Scientific Advisory Board Sample Clauses
The Scientific Advisory Board clause establishes a group of experts who provide scientific guidance and oversight to an organization or project. Typically, this clause outlines the board's composition, appointment process, and the scope of its advisory responsibilities, such as reviewing research strategies or evaluating technical proposals. Its core function is to ensure that decisions are informed by specialized knowledge, thereby enhancing the credibility and effectiveness of scientific endeavors.
POPULAR SAMPLE Copied 2 times
Scientific Advisory Board. The Company shall retain D▇. ▇▇▇▇▇▇▇▇▇▇▇▇ as an Advisor and the Advisor shall serve the Company as a member and Chairman of the SAB upon the terms and conditions hereinafter set forth. In serving the Company as a member of the SAB, the Advisor is acting in his individual capacity and not as an employee or representative of the Advisor’s Employer.
Scientific Advisory Board. The Company will maintain a Scientific Advisory Board (“SAB”) consisting of at least three (3) members. The initial members and chairperson of the SAB will be as set forth on EXHIBIT B. Any changes to the composition of the Scientific Advisory Board, including the removal or appointment of the chairperson, will be approved by the Board. The SAB will meet at least at least three time a year until December 31, 2009 and will initially be responsible for (i) advising the Company as to research goals and plans, (ii) reviewing research data and advising the Company with respect to interpretation of such research data, as requested by the Board, President or Chief Scientific Officer; and (iii) advising the Company with respect to research and development decisions, as requested by the Board, President or Chief Scientific Officer.
Scientific Advisory Board. Each member of the Company’s Scientific Advisory Board has executed a Consulting Agreement, substantially in the form attached hereto as Exhibit I.
Scientific Advisory Board. Each of ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇▇ and ▇▇▇▇▇ ▇▇▇ shall have been appointed as members of Cubist's Scientific Advisory Board.
Scientific Advisory Board. The functions of the Scientific Advisory Board, established pursuant to the La Jolla Agreement, shall be those set forth in Annex V. The Scientific Advisory Board shall be composed and shall operate in accordance with the provisions of Annex V.
Scientific Advisory Board. The Parties shall maintain the Scientific Advisory Board of technical specialists established pursuant to the La Jolla Agreement to assist the Director in matters regarding research to
Scientific Advisory Board. (A) During the Term, ViaCell shall arrange for at least one senior Amgen scientist identified by Amgen, who shall initially be ▇▇. ▇▇▇▇▇ ▇▇▇▇▇▇, Senior Director, Basic Research, Hematology (the "MSAB Nominee"), to serve as a member of ViaCell's Medical Scientific Advisory Board. Amgen, in its sole discretion, shall have the right to replace such MSAB Nominee at any time upon written notice to ViaCell.
(B) ViaCell shall retain the right at all times to exclude the MSAB Nominee from segments of its Medical Scientific Advisory Board meetings that do not relate to Cell Therapy Products or Collaboration Products. Amgen and the MSAB Nominee shall retain the right at all times to recuse the MSAB Nominee from any meeting or segments of a meeting of ViaCell's Scientific Advisory Board.
(C) The Parties understand and acknowledge that the MSAB Nominee is intended solely to provide ViaCell with strategic technical scientific input, and is not intended to confer on Amgen, the MSAB Nominee or any employees, officers or directors of Amgen any duties to ViaCell, including, without limitation, fiduciary duties or rights. ViaCell further understands that Amgen's employees, officers and directors owe duties solely to Amgen, its subsidiaries and Affiliates. Any advice provided by Amgen, its employees, officers and directors is provided with no warranties of any kind, and ViaCell shall indemnify, defend and hold Amgen harmless for any claims that may result from its reliance thereon.
Scientific Advisory Board. As long as Canaan owns not less than 250,000 shares of Series C Stock (or an equivalent amount of Class A Common Stock issued or issuable upon conversion thereof and, in any event, subject to appropriate adjustment for stock splits, stock dividends, combinations or the like), the Company and each of its majority-owned subsidiaries shall invite a representative of Canaan to participate as a member of its Scientific Advisory Board and shall reimburse such representative for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of such Scientific Advisory Boards or in connection with other activities engaged in by such representative at the request of the Company or such subsidiary.
Scientific Advisory Board. The Company shall provide to one designee of FCPR Genavent (“Genavent”) notice of, and the right to attend and observe, all meetings of the Company’s Scientific Advisory Board and copies of all written materials provided to members of the Scientific Advisory Board and furnish to Genavent copies of the minutes of such Scientific Advisory Board meetings as soon as practicable after adjournment thereof. The notice required pursuant to this Agreement shall be sent at substantially the same time and manner as notice is sent to the members of the Scientific Advisory Board.
Scientific Advisory Board. The Company will form a Scientific Advisory Board within 180 days of the date of this Agreement. That Scientific Advisory Board shall have five (5) initial members, and the Investor shall have the right to designate one (1) initial member, after consultation with the Company with respect to the identification of such members and function of such Board. The Company shall consult with Investor on the identity of the prospective Scientific Advisory Board initial members in good faith. No such member shall be a Competitor. The Investor shall assist the Company with respect to the indentification and recruitment of advisory board members and provide consultations on the function of one or more such advisory boards until the earlier to occur of (i) the date the Investor no longer meets the Observer Conditions and (ii) the date that is two years following the date of this Agreement.